Summary
Joy Yan is a biopharma executive, oncology physician-scientist, and serial founder with 11+ years leading global clinical development from first-in-human trials to large Phase 3 registrational programs. She has driven breakthrough regulatory strategies and was instrumental in BMS’s early FDA pilot programs for nivolumab and ipilimumab, and has led development across modalities including ADCs, bispecifics, TKIs, and cell-surface targets at J&J, Bayer, Ambrx and Hengrui. As CMO at Ambrx she designed adaptive Phase 1 strategies that helped secure a $2 billion M&A with J&J and later guided programs through global Phase 2/3 execution and IND/BLA/NDA submissions. At Hengrui she oversaw 300+ trials and multiple INDs and BLAs, and negotiated >$1B ex-China licensing, reflecting both scientific rigor and commercial savvy. A supportive team builder and strategic thinker, she blends hands-on clinical insight with regulatory and business development acumen. Based in West Windsor, NJ, she now co-founds an oncology/IMID biotech aiming for IPO/M&A by 2029, signaling a continued focus on translating novel biology into global medicines.
11 years of coding experience
Johns Hopkins University
Doctor of Medicine - MD, Clinical Medicine, Doctor of Medicine - MD, Clinical Medicine at 中国医科大学